• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Echo Therapeutics, Inc. (ECTE)

    -NasdaqCM
    1.63 Up 0.01(0.62%) May 27, 4:00PM EDT
    ProfileGet Profile for:
    Echo Therapeutics, Inc.
    99 Wood Avenue South
    Suite 302
    Iselin, NJ 08830
    United States - Map
    Phone: 732-201-4189
    Website: http://www.echotx.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:19

    Business Summary 

    Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Echo Therapeutics, Inc.

    Key Executives 
     PayExercised
    Mr. Scott W. Hollander , 50
    Chief Exec. Officer, Pres and Director
    420.00K0.00
    Mr. Alan W. Schoenbart CPA, 57
    Chief Financial Officer and Sec.
    260.00K0.00
    Mr. Thomas H. Bishop , 59
    VP of Operations and Product Devel.
    N/AN/A
    Ms. Christine H. Olimpio ,
    Director of Investor Relations & Corp. Communications
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders